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Vancomycin-intermediate S. aureusIn a collection of 50 pvl-positive Staphylococcus aureus isolates from 10 Rio de Janeiro hospitals, 18 (36%) were
from bloodstream infections, and 31 (62%) carried the SCCmec IV. Among 25 (50%) isolates of the USA1100/
ST30/CC30 lineage present in 8 hospitals, 1 isolate was characterized as vancomycin-intermediate S. aureus.+55-21-2560-8028.
ntos).© 2015 Elsevier Inc. All rights reserved.Staphylococcus aureus is an important cause of infections worldwide
(David and Daum, 2010), and the presence of genes that encode for
Panton-Valentine leukocidin (PVL) is associated to a wide range of
diseases, from uncomplicated to severe infections (Tristan et al.,
2007). The occurrence of PVL is associated with community-acquired
S. aureus isolates, both methicillin-resistant S. aureus (MRSA) and
methicillin-susceptible S. aureus (MSSA) (Boan et al., 2015). However,
recent reports had described the presence of hospital-acquired isolates
carrying these genes (Nichol et al., 2013), indicating a changing in
epidemiology of PVL-positive S. aureus isolates.
In the current study, we characterized 50 PVL-positive S. aureus
isolates, detected among 940 isolates of our collection and isolated
from 10 different hospitals in Rio de Janeiro, between 2004 and 2012.
They were isolated from bloodstream infections (BSIs) (18 isolates/
36%), skin and soft tissue infections (SSTIs) (11/22%), nostrils (9/18%),
and other clinical sources (12/24%).
The antimicrobial susceptibilitywas determined for 12 agents by the
disk diffusion method, according to the CLSI (2012), except for
mupirocin (Finlay et al., 1997) and tigecycline (European Committee
on Antimicrobial Susceptibility Testing, 2011). The MIC for oxacillin
and vancomycin was determined by broth microdilution test (CLSI,
2012). The mecA gene and SCCmec types were detected by PCR
(Milheiriço et al., 2007), and the clonal lineages were determined by
pulsed ﬁeld gel electrophoresis (PFGE) (Vivoni et al., 2005) and
Multilocus Sequence Typing (MLST) method (Enright et al., 2000). The
presence of genes that encode for adhesins, such as bbp (bone sialo-binding protein), cna (collagen-binding protein), ebpS (elastin-binding
protein), fnbB (ﬁbronectin-binding protein B) (Tristan et al., 2003),
and fnbA (ﬁbronectin-binding protein A) (Peacock et al., 2002), as well
as enterotoxins sea-see (Johnson et al., 1991; Lovseth et al., 2004; Mon-
day and Bohach, 1999) and seh (Sila et al., 2009), and toxin esfoliative
(tst) (Johnson et al., 1991) were investigated by PCR.
Among the 50 PVL-positive S. aureus isolates, 31 were MRSA and
carried the SCCmec type IV, and 20 of them were resistant only to
β-lactams. All 50 isolates were susceptible for linezolid, mupirocin,
rifampin, and tigecycline. The higher resistance rate was observed for
erythromycin (28%), and 14% were resistant to clindamycin, including
2 MSSA isolates with inducible resistance by erythromycin. MRSA
isolates presented oxacillin MIC90 of 16 μg/mL and for vancomycin of
2 μg/mL. For MSSA isolates, both the MIC90 values were 1 μg/mL (data
not shown). One isolate, number 1342a, which was obtained from
bloodstream infection of a male newborn, with 2405 g admitted at a
neonatal intensive care unit, suffering from meconium aspiration
syndrome exhibited vancomycin MIC of 4 μg/mL. It was conﬁrmed as
vancomycin-intermediate S. aureus (VISA) by populational analysis
proﬁle (PAP) (Nunes et al., 2006), and its agr polymorphism was
determined (Gilot et al., 2002) as type 3 (Supplementary Material).
S. aureus isolates were distributed in 15 lineages, with most of the
isolates (35/70%) included in 3 lineages: USA1100/ST30/CC30 (25 iso-
lates), USA400/ST1/CC1 (7 isolates) and USA800/ST/CC5 (3 isolates),
and 94% of these isolates were MRSA (Fig. 1). The ST2369 of the CC30
was described for the ﬁrst time in the present study. The USA1100/
ST30/CC30 isolates were present in 8 hospitals, between 2006 and
2009 and in 2012. Eighteen (72%) of them were detected as MRSA and
presented the same PFGE subtype (Table 1). These identical isolates
Fig. 1.Dendrogram of the PFGE patterns and characteristics related to the genetic background of 50 PVL-positive S. aureus isolates. Isolates showing a similarity coefﬁcient ≥80%were con-
sidered genetically related. ST = sequence type; CC = clonal complex. One isolate, 1155a, was used as control of the USA1100/ST30 A1 pulsotype (Schuenck et al., 2012).
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isolates presenting similar resistance and virulence gene proﬁles were
recovered at hospital H1. Similarly, 4 isolates were recovered from
blood of newborns at hospital H3 in a period of 5 months during 2009.
One of these isolates (number 1342) was characterized as VISA.
Among the virulence genes analyzed, the bbp was found in all
USA1100/ST30/CC30 isolates (P b 0.05), and the sehwas related to the
USA400/ST1/CC1 isolates (P b 0.05). Overall, the enterotoxins genes
were not related to a speciﬁc lineage, being the sea gene the most
prevalent one (80%). Some virulence genes were rare, such as the fnbB
gene found in 2 isolates (USA300/ST8 and ST97 lineages) and the tst
gene, related to the ST484/CC30 and ST97/CC1 isolates.
S. aureus PVL-positive isolates have been related to severe disease
(Tristan et al., 2007; Cavalcante et al., 2015) making its characterization
very important. Furthermore, analysis of a collection of bacterial isolates
having a common characteristic, such as PVL genes, can help to
understand the relationship between them. However, in general,
available studies demonstrate only the occurrence of these isolates
(Nichol et al., 2013; Cavalcante et al., 2015; Caboclo et al., 2013; Egea
et al., 2014; Fernandez et al., 2012; Schuenck et al., 2012). In the present
study, we analyzed a collection of 50 PVL-positive S. aureus isolates
obtained in a 6-year period in Rio de Janeiro hospitals as their phenotyp-
ic and molecular characteristics. Despite most of our isolates present a
community-associated proﬁle, we could not inferred that our isolates
were community acquired, as we did not had access to most patient's
clinical data, such as day of admission and previous risk factors for
MRSA infection, being this is a limiting factor of the study.The USA1100/ST30/CC30 lineage was present in majority of Rio de
Janeiro hospitals. This lineage carrier of PVL genes had already been
reported in Argentina (Egea et al., 2014; Fernandez et al., 2012) and in
Brazil (Cavalcante et al., 2015; Caboclo et al., 2013; Schuenck et al.,
2012). Moreover, in the present study, a VISA isolate belonging to
USA1100/ST30 was identiﬁed, indicating the relevance of this lineage
among the PVL-positive MRSA isolates. Although there are studies
reporting the occurrence of S. aureus isolates carrying the PVL genes
capable to express the heterogeneous vancomycin-intermediate
S. aureus (hVISA) phenotype (Maor et al., 2009), to our knowledge,
this is the ﬁrst study to identify a PVL-positive VISA isolate belonging
to USA1100/ST30/CC30 lineage.
The bbp virulence gene, whose presence could be associated to oste-
omyelitis and arthritis (Tristan et al., 2003) had been related to the ST30
S. aureus lineage found in an orthopedic hospital (Schuenck et al., 2012).
Here, we also found a correlation between the ST30 and the bbp gene,
suggesting that this gene could be a possiblemarker of this lineage. Sim-
ilarly, we observed that the seh gene was associated with the USA400/
ST1/CC1 lineage, as previously reported (Tristan et al., 2007). It is
interesting to mention that, although the USA400 lineage is becoming
prevalent in Brazilian hospitals, it is usually negative for PVL genes
(Caboclo et al., 2013; Schuenck et al., 2012), contrary to what is
observed at the USA (Tristan et al., 2007).
Further studies characterizing such a collection of PVL-positive
S. aureus isolates and their relationship to genetic backgrounds are
necessary, as these lineages are becomingmore common in the hospital
environment affecting patients already debilitated. This study showed a
Table 1
Clinical and microbiological aspects of 25 isolates belonging to the PVL-positive Brazilian prevalent lineage USA1100/ST30/CC30.
Hospital
(number of isolates)
Isolation date
(dd/mm/yy)
Isolation source PFGE proﬁle SCCmec type Resistance proﬁle MIC (mg/mL) Virulence genes proﬁlea
OXA VAN
H1 (n = 11)
601 09/01/2006 SSTI A1 IV fox, eri 4 0.5 fnbA, sea, seb
596 02/02/2006 SSTI A1 IV fox 4 2 fnbA, sea
809 06/07/2006 Nostril A1 IV fox 4 1 sea, seb, seh
806 16/08/2006 Nostril A1 IV fox 2 1 sea
826 24/10/2006 BSI A1 IV fox 1 1 fnbA, sea, seb
827 24/10/2006 SSTI A1 IV fox 1 1 fnbA, sea, seh
932 14/11/2006 Nostril A1 IV fox 0.5 1 seh
943 14/11/2006 SSTI A1 IV fox 8 1 fnbA, sea, seh
1086 10/01/2008 BSI A4 NA NA 0.25 1 fnbA, sea
1079 03/04/2008 BSI A6 NA sut 0.125 1 NA
1195 20/05/2008 BSI A4 NA sut, tet 0.125 1 fnbA, sea, seb
H2 (n = 3)
1155 03/05/2006 Bone secretion A1 IV fox 8 1 fnbA, sea
1165 01/08/2006 SSTI A4 NA sut, tet 0.5 1 fnbA, sea, seb
1174 17/01/2007 SSTI A5 NA clo 1 1 fnbA
H3 (n = 4)
1341 24/02/2009 BSI A1 IV fox 2 2 sea
1342 24/03/2009 BSI A1 IV fox 8 4 sea
1343 30/03/2009 BSI A1 IV fox 2 2 fnbA, sea
1352 10/06/2009 BSI A1 IV fox 2 2 fnbA, sea, seh
H5 (n = 1)
1012 20/08/2007 BSI A1 IV fox, cli, eri 4 0.5 fnbA, sea
H6 (n = 1)
1013 22/08/2007 SSTI A1 IV fox, tec 1 1 fnbA, sea, seb
H7 (n = 2)
1179 05/02/2009 SSTI A1 IV fox 8 1 fnbA, sea
1180 09/02/2009 SSTI A1 IV fox, eri, tet 16 1 sea
H8 (n = 2)
1463 18/04/2012 SSTI A1 IV fox 4 1 sec, sed, see
1462 18/04/2012 SSTI A3 NA clo 2 2 sec, sed, see
H10 (n = 1)
1025 18/11/2007 SSTI A2 IV fox 4 1 fnbA, sea
SSTI = skin and soft tissue infection; BSI = bloodstream infection; NA = Not applicable (MSSA isolates); fox = cefoxitin; eri = erythromycin; cli = clindamycin; tec = teicoplanin;
tet = tetracycline; OXA = oxacillin; VAN = vancomycin.
a All isolates also presented the adhesion genes: bbp, ebpS, cna, clfA, and clfB.
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of Rio de Janeiro hospitals and its association with the bbp gene.
Moreover, the occurrence of a VISA isolate causing bloodstream
infection in a newborn, among this well-adapted PVL-positive MRSA
lineage is of great concern, since vancomycin is the antimicrobial of
choice to treat invasive MRSA infections.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.diagmicrobio.2015.09.004.
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